| Literature DB >> 28367083 |
Ching-Hung Lin1, Chen-Chung Liao2, Chi-Huang Huang3, Yu-Tang Tung4, Huan-Cheng Chang5, Mei-Chich Hsu6, Chi-Chang Huang4.
Abstract
Globally, the proportion of older adults is increasing. Older people face chronic conditions such as sarcopenia and functional decline, which are often associated with disability and frailty. Proteomics assay of potential serum biomarkers of frailty in older adults. Older adults were divided into non-frail and frail groups (n = 6 each; 3 males in each group) in accordance with the Chinese-Canadian Study of Health and Aging Clinical Frailty Scale. Adults were measured for grip power and the 6-min walk test for physical activity, and venous blood was sampled after adults fasted for 8 h. Ultra-high-performance liquid chromatography-tandem mass spectrometry was used for proteomics assay. The groups were compared for levels of biomarkers by t test and Pearson correlation analysis. Non-frail and frail subjects had mean age 77.5±0.4 and 77.7±1.6 years, mean height 160.5±1.3 and 156.6±2.9 cm and mean weight 62.5±1.2 and 62.8±2.9 kg, respectively. Physical activity level was lower for frail than non-frail subjects (grip power: 13.8±0.4 vs 26.1±1.2 kg; 6-min walk test: 215.2±17.2 vs 438.3±17.2 m). Among 226 proteins detected, for 31, serum levels were significantly higher for frail than non-frail subjects; serum levels of Ig kappa chain V-III region WOL, COX7A2, and albumin were lower. The serum levels of ANGT, KG and AT were 2.05-, 1.76- and 2.22-fold lower (all p < 0.05; Figure 1A, 2A and 3A) for non-frail than frail subjects and were highly correlated with grip power (Figure 1B, 2B and 3B). Our study found that ANGT, KG and AT levels are known to increase with aging, so degenerated vascular function might be associated with frailty. In total, 226 proteins were revealed proteomics assay; levels of angiotensinogen (ANGT), kininogen-1 (KG) and antithrombin III (AT) were higher in frail than non-frail subjects (11.26±2.21 vs 5.09±0.74; 18.42±1.36 vs 11.64±1.36; 22.23±1.64 vs 9.52±0.95, respectively, p < 0.05). These 3 factors were highly correlated with grip power (p < 0.05), with higher correlations between grip power and serum levels of ANGT (r = -0.89), KG (r = -0.90), and AT (r = -0.84). In conclusion, this is the first study to demonstrate a serum proteomic profile characteristic of frailty in older adults. Serum ANGT, KG and AT levels could be potential biomarkers for monitoring the development and progression of frailty in older adults.Entities:
Keywords: Angiotensinogen; Antithrombin III; Kininogen-1; Proteomics; Strength
Mesh:
Substances:
Year: 2017 PMID: 28367083 PMCID: PMC5370285 DOI: 10.7150/ijms.17627
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Characteristics of non-frailty and frailty subjects.
| Variable | Non-Frailty | Frailty |
|---|---|---|
| Sex (men/women, n) | (3/3) | (3/3) |
| Age (yr) | 77.5 ± 0.4 | 77.7 ± 1.6 |
| Height (cm) | 160.5 ± 1.3 | 156.6 ± 2.9 |
| Body weight (kg) | 62.5 ± 1.2 | 62.8 ± 2.9 |
| Heart rate (beats/min) | 77.2 ± 4.9 | 77.5 ± 1.7 |
| SBP (mmHg) | 147.3 ± 8.8 | 135.3 ± 9.9 |
| DBP (mmHg) | 85.2 ± 11.0 | 80.7 ± 12.0 |
| Right hand grip strength (kg) | 27.3 ± 1.3 | 14.3 ± 0.6* |
| Left hand grip strength (kg) | 25.0 ± 1.2 | 13.4 ± 0.4* |
| Grip power (kg) | 26.1 ± 1.2 | 13.8 ± 0.4* |
| 6-min-walk distance (m) | 438.3 ± 17.2 | 215.2 ± 17.2* |
| 6-min-walk speed (m/min) | 73.1 ± 2.9 | 35.9 ± 2.9* |
Data are mean ± SEM for n = 6 subjects per group. Data in the same row with superscript symbol “ * ” differ significantly, p < 0.05 by t-test. SBP, systolic blood pressure; DBP, diastolic blood pressure.
Differentially expressed proteins in non-frailty and frailty samples
| Protein-ID | Protein Name | Non-Frailty | Frailty | Fold | |
|---|---|---|---|---|---|
| P01623 | Ig kappa chain V-III region WOL | 4.68 ± 0.51 | 1.28 ± 0.92 | 0.0089 | -3.65 |
| Q496I0 | COX7A2 protein | 13.15 ± 1.97 | 6.23 ± 1.47 | 0.0184 | -2.11 |
| P02768 | Serum albumin | 1466.80 ± 25.91 | 1247.41 ± 23.88 | 0.0001 | -1.18 |
| P00450 | Ceruloplasmin | 97.02 ± 1.59 | 116.98 ± 4.73 | 0.0025 | 1.21 |
| Q5T985 | Inter-alpha-trypsin inhibitor heavy chain H2 | 54.63 ± 3.76 | 69.59 ± 2.65 | 0.0086 | 1.27 |
| P08603 | Complement factor H | 71.63 ± 2.55 | 94.21 ± 3.99 | 0.0008 | 1.32 |
| Q9UP60 | SNC73 protein | 79.39 ± 7.37 | 105.07 ± 3.13 | 0.0094 | 1.32 |
| P02790 | Hemopexin | 31.81 ± 1.80 | 42.12 ± 3.25 | 0.0197 | 1.32 |
| P01009 | Alpha-1-antitrypsin | 66.29 ± 6.92 | 97.8 ± 8.74 | 0.0180 | 1.48 |
| Q9P173 | PRO2275 | 27.50 ± 2.00 | 40.91 ± 3.41 | 0.0069 | 1.49 |
| P10643 | Complement component C7 | 8.22 ± 0.98 | 12.36 ± 0.86 | 0.0098 | 1.50 |
| D3DNU8 | Kininogen 1, isoform CRA_a | 11.64 ± 1.36 | 18.42 ± 1.36 | 0.0055 | 1.58 |
| P04004 | Vitronectin | 10.67 ± 0.77 | 17.21 ± 1.61 | 0.0043 | 1.61 |
| P02763 | Alpha-1-acid glycoprotein 1 | 5.20 ± 1.24 | 9.36 ± 0.48 | 0.0109 | 1.8 |
| B4E1Z4 | Complement factor B | 21.69 ± 5.52 | 41.87 ± 3.8 | 0.0131 | 1.93 |
| Q6MZV7 | Putative uncharacterized protein | 52.13 ± 8.60 | 100.89 ± 11.98 | 0.0080 | 1.94 |
| C9JV77 | Alpha-2-HS-glycoprotein | 3.58 ± 0.82 | 7.62 ± 0.79 | 0.0054 | 2.13 |
| B4E1C2 | Kininogen 1, isoform CRA_b | 6.19 ± 1.98 | 13.30 ± 1.37 | 0.0146 | 2.15 |
| Q86U78 | Angiotensinogen (Serine (Or cysteine) proteinase inhibitor, clade A | 5.09 ± 0.74 | 11.26 ± 2.21 | 0.0246 | 2.21 |
| P13671 | Complement component C6 | 6.44 ± 1.10 | 14.36 ± 0.70 | 0.0001 | 2.23 |
| P04003 | C4b-binding protein alpha chain | 5.88 ± 1.18 | 13.15 ± 1.97 | 0.0101 | 2.24 |
| G3V5I3 | Alpha-1-antichymotrypsin | 11.18 ± 2.23 | 25.32 ± 3.10 | 0.0041 | 2.27 |
| P01008 | Antithrombin III | 9.52 ± 0.95 | 22.23 ± 1.64 | 0.0000 | 2.33 |
| P01598 | Ig kappa chain V-I region EU | 0.95 ± 0.43 | 2.29 ± 0.41 | 0.0469 | 2.41 |
| P10909 | Clusterin | 3.94 ± 1.21 | 10.04 ± 2.07 | 0.0294 | 2.55 |
| P00738 | Haptoglobin | 9.03 ± 4.16 | 27.16 ± 3.27 | 0.0065 | 3.01 |
| P01031 | Complement C5 | 3.48 ± 1.04 | 11.21 ± 2.55 | 0.0185 | 3.22 |
| Q68CX6 | Putative uncharacterized protein DKFZp686O13149 | 16.56 ± 10.50 | 55.57 ± 6.67 | 0.0106 | 3.35 |
| P01777 | Ig heavy chain V-III region TEI | 3.68 ± 1.00 | 12.92 ± 1.68 | 0.0008 | 3.51 |
| Q68CK4 | Leucine-rich alpha-2-glycoprotein | 0.98 ± 0.64 | 3.64 ± 0.90 | 0.0375 | 3.72 |
| Q6MZV6 | Putative uncharacterized protein DKFZp686L19235 | 3.12 ± 3.12 | 17.23 ± 5.50 | 0.0498 | 5.52 |
| O75882 | Attractin | 0.57 ± 0.57 | 3.38 ± 0.33 | 0.0016 | 5.97 |
| P09871 | Complement C1s subcomponent | 0.78 ± 0.78 | 4.68 ± 0.79 | 0.0054 | 6.02 |
| P02748 | Complement component C9 | 0.75 ± 0.49 | 4.88 ± 0.58 | 0.0003 | 6.55 |
| P19652 | Alpha-1-acid glycoprotein 2 | N.D.a | 2.04 ± 0.72 | 0.0179 | + |
| Q9H382 | Fibronectin 1 | N.D. | 2.72 ± 1.12 | 0.0357 | + |
| F8W7M9 | Fibulin-1 | N.D. | 1.98 ± 0.78 | 0.0291 | + |
| P01596 | Ig kappa chain V-I region CAR | N.D. | 1.21 ± 0.40 | 0.0121 | + |
| P01620 | Ig kappa chain V-III region SIE | N.D. | 3.93 ± 1.01 | 0.0031 | + |
| P04208 | Ig lambda chain V-I region WAH | N.D. | 0.84 ± 0.38 | 0.0494 | + |
| Q6GMX6 | IGH@ protein | N.D. | 59.01 ± 8.84 | 0.0001 | + |
| Q9NVE5 | Ubiquitin carboxyl-terminal hydrolase 40 | N.D. | 1.49 ± 0.47 | 0.0102 | + |
| D3DVD8 | Spectrin, alpha, erythrocytic 1 (Elliptocytosis 2), isoform CRA_c | 3.56 ± 1.07 | N.D. | 0.0077 | - |
Mean ± SEM. *N.D., not detectable.
Figure 1(A) Serum levels of angiotesinogen (ANG) in frailty and non-frailty. *, p < 0.05. (B) Relationship between the grip power and serum ANG level. Serum ANG level was negatively correlated with grip power (r = -0.89, p < 0.05) in elders with non-frailty. Elders with frailty and non-frailty are represented by the filled triangles and open circles, respectively.
Figure 2(A) Serum levels of kininogen-1 (KG) in frailty and non-frailty. *, p < 0.05. (B) Relationship between grip power and serum KG level. Serum KG level was negatively correlated with grip power (r = -0.90, p < 0.05) in elders with frailty. Elders with frailty and non-frailty are represented by the filled triangles and open circles, respectively.